Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed prostate cancer

- Previously untreated disease prior to participation on protocol
JUSMH-BRI-GU05-01

- Intermediate-risk disease as defined by the following:

- Clinical stage < T2c

- Prostate-specific antigen (PSA) ≤ 20 ng/mL

- Gleason score < 8

- Previously enrolled on protocol JUSMH-BRI-GU05-01

PATIENT CHARACTERISTICS:

- ECOG performance status 0-1

- Life expectancy ≥ 3 months

- WBC ≥ 2,000/μL

- Hemoglobin ≥ 10.0 g/dL

- Platelet count ≥ 100,000/μL

- Serum creatine level ≤ 2.0 mg/dL

- ALT and AST ≤ 100 IU/L

- No other cancer requiring treatment

- No poorly controlled hypertension (i.e., diastolic blood pressure ≥ 120 mm Hg)

- No severe psychiatric disorders, including schizophrenia or dementia

- No poorly controlled diabetes

- Considered appropriate for study participation, as determined by the Principal
Investigator or Clinical Investigator

PRIOR CONCURRENT THERAPY:

- No prior drugs for benign prostatic hyperplasia (other than antiandrogen therapy)

- No prior surgery for prostate cancer

- No concurrent steroid drugs (except for ointment)

- No other concurrent antiandrogen therapy